Calmark delivers first products to Kenya
As part of the cooperation between Calmark Sweden AB and VIA Global Health, and in the context of the parties’ ongoing launch campaign in Africa, the Company announces today that a first demo order from Kenya has been received and is about to be delivered. Today’s order is of less economic importance, but highly significant in a launch perspective.
As previously disclosed, Calmark has a cooperation agreement with VIA Global Health, an operator with local distributors in more than 80 countries. The operator's main focus is on low- and middle-income countries, and the goal is to enable distribution of essential medical devices in parts of the world where the need is urgent but where regular launches are often not a priority for most manufacturers.
VIA Global has strengthened its organization across Africa and sales efforts are now intensifying. Calmark's products are an essential part of this campaign. To this end, the first demo products are now dispatched to Kenya in view of the initial sales work targeting local distributors.
“VIA Global Health is a key partner for us, addressing those markets where our products stand to make a significant difference,” says Anna Söderlund, CEO. “Calmark continues its worldwide launch. It is an important milestone for us that products are now on their way to this part of Africa.”
This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 19-07-2022 14:27 CET.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.